Merck Keytruda approved as lung cancer monotherapy in China

The National Medical Products Administration in China approves Merck’s (NYSE:MRK) KEYTRUDA as monotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA is now the first anti-PD-1 therapy approved in China as both monotherapy and in combination with chemotherapy for the first-line treatment of patients with NSCLC.

https://seekingalpha.com/news/3503255-merck-s-keytruda-approved-monotherapy-china-patients-nsclc